AQR Capital Management LLC Purchases New Shares in Collegium Pharmaceutical Inc (NASDAQ:COLL)

AQR Capital Management LLC purchased a new stake in Collegium Pharmaceutical Inc (NASDAQ:COLL) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 24,334 shares of the specialty pharmaceutical company’s stock, valued at approximately $320,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. First Quadrant L P CA boosted its stake in Collegium Pharmaceutical by 87.2% in the 2nd quarter. First Quadrant L P CA now owns 4,484 shares of the specialty pharmaceutical company’s stock valued at $59,000 after purchasing an additional 2,089 shares during the period. DekaBank Deutsche Girozentrale boosted its stake in Collegium Pharmaceutical by 22.2% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 13,200 shares of the specialty pharmaceutical company’s stock valued at $221,000 after purchasing an additional 2,400 shares during the period. Northern Trust Corp boosted its stake in Collegium Pharmaceutical by 1.1% in the 2nd quarter. Northern Trust Corp now owns 387,440 shares of the specialty pharmaceutical company’s stock valued at $5,095,000 after purchasing an additional 4,201 shares during the period. Bank of New York Mellon Corp boosted its stake in Collegium Pharmaceutical by 2.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 189,543 shares of the specialty pharmaceutical company’s stock valued at $2,492,000 after purchasing an additional 4,524 shares during the period. Finally, GSA Capital Partners LLP boosted its stake in Collegium Pharmaceutical by 11.3% in the 2nd quarter. GSA Capital Partners LLP now owns 71,802 shares of the specialty pharmaceutical company’s stock valued at $944,000 after purchasing an additional 7,313 shares during the period. Institutional investors and hedge funds own 92.08% of the company’s stock.

NASDAQ:COLL opened at $11.79 on Friday. The stock has a fifty day moving average price of $11.47 and a 200-day moving average price of $12.46. The company has a market cap of $398.29 million, a price-to-earnings ratio of -9.91 and a beta of 0.52. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.20 and a current ratio of 1.25. Collegium Pharmaceutical Inc has a fifty-two week low of $10.01 and a fifty-two week high of $19.83.



Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Wednesday, August 7th. The specialty pharmaceutical company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.05. The firm had revenue of $75.04 million during the quarter, compared to the consensus estimate of $75.77 million. Collegium Pharmaceutical had a negative return on equity of 26.10% and a negative net margin of 7.45%. The company’s revenue was up 2.7% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.40) EPS. Research analysts predict that Collegium Pharmaceutical Inc will post -0.37 EPS for the current fiscal year.

In related news, Director Michael Thomas Heffernan sold 25,000 shares of the company’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $11.26, for a total transaction of $281,500.00. Following the completion of the sale, the director now directly owns 132,069 shares in the company, valued at approximately $1,487,096.94. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director David Hirsch sold 22,106 shares of the company’s stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $11.65, for a total value of $257,534.90. Following the sale, the director now owns 64,223 shares of the company’s stock, valued at $748,197.95. The disclosure for this sale can be found here. Corporate insiders own 8.08% of the company’s stock.

Several analysts recently issued reports on the company. Zacks Investment Research downgraded Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Friday. BidaskClub upgraded Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Tuesday, August 13th. ValuEngine upgraded Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Cantor Fitzgerald reiterated an “overweight” rating and set a $24.00 target price (down from $35.00) on shares of Collegium Pharmaceutical in a research report on Thursday, August 8th. Finally, William Blair reiterated a “buy” rating on shares of Collegium Pharmaceutical in a research report on Tuesday, September 17th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Collegium Pharmaceutical currently has a consensus rating of “Buy” and an average target price of $24.00.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.

Featured Story: Holder of Record

Want to see what other hedge funds are holding COLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Collegium Pharmaceutical Inc (NASDAQ:COLL).

Institutional Ownership by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.